Haibu Pharmaceutical

Beijing Haibu Pharmaceutical Technology Co., Ltd., established in 2005, is a high-tech enterprise with the core capability of 'chemical drug R&D + integrated API and formulation'. It has a subsidiary, Haibu Drug Research Institute. The company is mainly engaged in technical development and transfer of chemical drugs, R&D and incubation of innovative drugs, MAH drug R&D, registration and sales, and associated registration and commercial supply of APIs and pharmaceutical intermediates. It also holds import and export rights for technology and goods. Haibu Pharmaceutical has extensive experience in innovative R&D and registration applications for various dosage forms including chemical APIs, oral solids, liquid preparations, inhalation preparations, sterile injections, and topical preparations. Its research areas cover multiple indications such as oncology, psychiatry and neurology, cardiovascular and cerebrovascular diseases, digestive system, and respiratory system. The company continuously conducts research, incubation, and cooperation on Class 1 innovative drugs and improved drugs. The Haibu team is well-versed in relevant laws, regulations, and technical guidelines for chemical drug development, and possesses full-process project management capabilities from project evaluation, patent strategy design, preclinical research, clinical trial management, drug registration, to product market approval, ensuring the progress, quality, efficiency, and registration success rate of ongoing projects.